Story thread · 3 reports / 3 sources
FDA approves first radioligand generic, setting up rivalry with Novartis
endpts.com · 7h · first report
How the coverage leans
Across 3 sources · syndicated copies counted once
For the first time, Novartis’ leadership in the radioligand field will be tested by a generic rival. Curium announced on Monday that the FDA has approved its “radioligand equivalent” to Novartis’ Lutathera for the treatment ...
The coverage
- FDA clears first generic radioligand drug; Sionna turns to layoffs
biopharmadive.com · 2h
- Novartis' Lutathera now facing generic competition from Cirium's Bexlutry
seekingalpha.com · 3h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.